Stock Analysis on Net

Allergan PLC (NYSE:AGN)

$22.49

This company has been moved to the archive! The financial data has not been updated since May 7, 2020.

Analysis of Profitability Ratios
Quarterly Data

Microsoft Excel

Paying user area


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Profitability Ratios (Summary)

Allergan PLC, profitability ratios (quarterly data)

Microsoft Excel
Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016
Return on Sales
Gross profit margin
Operating profit margin
Net profit margin
Return on Investment
Return on equity (ROE)
Return on assets (ROA)

Based on: 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31), 10-K (reporting date: 2016-12-31), 10-Q (reporting date: 2016-09-30), 10-Q (reporting date: 2016-06-30), 10-Q (reporting date: 2016-03-31).


The financial indicators demonstrate distinct trends and fluctuations over the reported quarterly periods, reflecting changes in profitability and efficiency metrics.

Gross Profit Margin
The gross profit margin shows a notable improvement from 73.17% in March 2016 to a peak around 87.56% in March 2017. Thereafter, it maintains a relatively stable range mostly between 83.73% and 86.56%, with a gentle decreasing trend observed towards March 2020, ending at 83.73%. This suggests the company sustained strong control over its production costs relative to its sales throughout the period, despite a slight decline in the most recent quarters.
Operating Profit Margin
The operating profit margin is highly volatile and predominantly negative across the periods. Starting at -15.77% in March 2016, the margin deteriorates further in some quarters, reaching lows of approximately -60.39% in September 2019. Although there are sporadic improvements, such as a brief rise to -5.95% in September 2018, the overall trend indicates significant operating challenges and persistent operating losses over time, with a partial recovery in the latest quarters ending at -21.34% in March 2020.
Net Profit Margin
The net profit margin exhibits extreme variability, with several quarters reporting strong positive margins exceeding 100% in some instances (notably 107.27% in September 2016 and 102.76% in December 2016). However, following this period, margins shift sharply negative, with values as low as -58.5% in September 2019, indicating episodes of net losses. The negative trend persists with some volatility, and while the margin improves slightly towards March 2020, it remains negative at -15.44%. This pattern reflects significant fluctuations in net profitability, likely influenced by extraordinary items or non-operating factors.
Return on Equity (ROE)
The ROE reflects a similar pattern to net profit margins, with positive returns up to December 2016, peaking at 19.65%, followed by a marked decline into negative territory from March 2017 onwards. Negative ROE values deepen over the successive quarters, reaching around -15.82% in September 2019, indicating the company struggled to generate profit from shareholders' equity during this phase. There is a modest improvement in early 2020, but the ROE remains negative at -4.28%, highlighting ongoing challenges in equity profitability.
Return on Assets (ROA)
The ROA trend parallels that of ROE, starting with positive returns (3.44% in March 2016, rising to 11.61% in December 2016) before turning negative from March 2017 onwards. The lowest ROA occurs near -9.8% in September 2019, indicating ineffective asset utilization during this period. Slight improvement appears by March 2020 with ROA at -2.81%, though it remains below zero. These values suggest operational inefficiencies and diminished asset productivity over much of the reported timeline.

In summary, while the gross profit margin remains relatively robust, the operating and net profit margins alongside returns on equity and assets reveal considerable financial strain throughout most of the periods. Repeated negative profitability and returns metrics imply significant challenges in controlling operational costs and generating returns from investments and equity. The modest recovery noted in some ratios toward the final quarters suggests initial signs of financial stabilization, however, overall performance remains below optimal levels.


Return on Sales


Return on Investment


Gross Profit Margin

Allergan PLC, gross profit margin calculation (quarterly data)

Microsoft Excel
Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016
Selected Financial Data (US$ in thousands)
Gross profit
Net revenues
Profitability Ratio
Gross profit margin1
Benchmarks
Gross Profit Margin, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31), 10-K (reporting date: 2016-12-31), 10-Q (reporting date: 2016-09-30), 10-Q (reporting date: 2016-06-30), 10-Q (reporting date: 2016-03-31).

1 Q1 2020 Calculation
Gross profit margin = 100 × (Gross profitQ1 2020 + Gross profitQ4 2019 + Gross profitQ3 2019 + Gross profitQ2 2019) ÷ (Net revenuesQ1 2020 + Net revenuesQ4 2019 + Net revenuesQ3 2019 + Net revenuesQ2 2019)
= 100 × ( + + + ) ÷ ( + + + ) =

2 Click competitor name to see calculations.


Gross Profit
The gross profit exhibited a generally upward trend from the first quarter of 2016 through the end of 2019, reaching a peak in the last quarter of 2019 at approximately 3,647,000 thousand US dollars. Despite some fluctuations, the gross profit increased seasonally each year. However, in the first quarter of 2020, there was a noticeable decline to about 2,981,300 thousand US dollars, signaling a potential disruption or negative impact at the start of 2020.
Net Revenues
Net revenues followed a consistent growth pattern over the observed periods, increasing from approximately 3,399,300 thousand US dollars in the first quarter of 2016 to a high of around 4,351,000 thousand US dollars in the last quarter of 2019. This upward momentum aligns with the increase in gross profit, indicating expanding sales volumes or pricing improvements. Nonetheless, a similar decline occurred in the first quarter of 2020, with net revenues falling to roughly 3,604,400 thousand US dollars, which represents a notable reduction compared to the previous quarters.
Gross Profit Margin
Gross profit margin exhibited strong improvement from the first quarter of 2016 through the end of 2016, increasing significantly from about 73.17% to above 87%. Thereafter, the margin stabilized within the mid-80% range, fluctuating mildly between approximately 83.7% and 87.6% across subsequent quarters. From early 2017 to 2019, the margins remained consistently high, although a slight gradual decrease can be observed towards the end of the period, declining from around 86.2% in early 2019 to about 83.73% in the first quarter of 2020. This suggests a potential incremental rise in cost of goods sold or pricing pressures affecting profitability.
Overall Analysis
The data reveals a company that experienced sustained growth in both gross profit and net revenues over nearly four years, supported by a relatively high and stable gross profit margin. The peak performance occurred in late 2019, possibly reflecting successful operational or market conditions. However, the first quarter of 2020 shows a downturn across all key metrics, implying emerging challenges that could stem from external factors impacting sales and profitability. The slight deterioration in gross profit margin also hints at increasing cost pressures or margin compression that might warrant further investigation.

Operating Profit Margin

Allergan PLC, operating profit margin calculation (quarterly data)

Microsoft Excel
Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016
Selected Financial Data (US$ in thousands)
Operating income (loss)
Net revenues
Profitability Ratio
Operating profit margin1
Benchmarks
Operating Profit Margin, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31), 10-K (reporting date: 2016-12-31), 10-Q (reporting date: 2016-09-30), 10-Q (reporting date: 2016-06-30), 10-Q (reporting date: 2016-03-31).

1 Q1 2020 Calculation
Operating profit margin = 100 × (Operating income (loss)Q1 2020 + Operating income (loss)Q4 2019 + Operating income (loss)Q3 2019 + Operating income (loss)Q2 2019) ÷ (Net revenuesQ1 2020 + Net revenuesQ4 2019 + Net revenuesQ3 2019 + Net revenuesQ2 2019)
= 100 × ( + + + ) ÷ ( + + + ) =

2 Click competitor name to see calculations.


Operating Income (Loss) Trend
The operating income exhibits significant volatility and generally negative values throughout the periods reviewed. Notably, there are substantial losses in the quarters ending June 30, 2016 (-487.6 million) and September 30, 2017 (-4.0223 billion), indicating episodes of considerable financial strain. The magnitude of operating losses peaks in December 31, 2018 (-5.3841 billion) and March 31, 2019 (-2.3092 billion), followed by a somewhat reduced but still negative trend toward the end of the timeline, with the March 31, 2020 quarter showing a loss of -1.2996 billion.
Net Revenues Pattern
Net revenues display relative stability with fluctuations but no clear upward or downward trajectory. Values range approximately between 3.4 billion and 4.4 billion across quarters, indicating consistent gross revenue generation. There are recurring peaks notably in quarters ending in December 31, 2017 (4.3261 billion) and December 31, 2019 (4.351 billion), reflecting possible seasonal or operational factors influencing sales. Despite the losses in operating income, net revenues remain steady, suggesting cost or expense issues impacting profitability rather than revenue generation.
Operating Profit Margin Analysis
The operating profit margin is persistently negative, reinforcing the pattern of operating losses. Margins worsen dramatically during certain quarters, such as September 30, 2017 (-43.48%) and December 31, 2019 (-60.39%), evidencing periods of acute operational inefficiency or high costs relative to revenues. Some improvement is noted toward the quarter ending September 30, 2018 (-5.95%), but this is short-lived, and overall margins remain deeply negative, consistently below -10% and frequently much worse.
Overall Financial Health Insight
The data suggests ongoing operational challenges with recurrent and large operating losses despite stable revenue streams. The extreme variability and negative profitability metrics point toward potential structural issues such as elevated expenses, impairment charges, or other extraordinary costs severely impacting earnings. Consistent negative operating margins underscore the need for strategic review to address cost management and enhance operational efficiency. The absence of positive operating income in the periods reviewed indicates a sustained inability to translate revenues into profits.

Net Profit Margin

Allergan PLC, net profit margin calculation (quarterly data)

Microsoft Excel
Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016
Selected Financial Data (US$ in thousands)
Net income (loss) attributable to shareholders
Net revenues
Profitability Ratio
Net profit margin1
Benchmarks
Net Profit Margin, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31), 10-K (reporting date: 2016-12-31), 10-Q (reporting date: 2016-09-30), 10-Q (reporting date: 2016-06-30), 10-Q (reporting date: 2016-03-31).

1 Q1 2020 Calculation
Net profit margin = 100 × (Net income (loss) attributable to shareholdersQ1 2020 + Net income (loss) attributable to shareholdersQ4 2019 + Net income (loss) attributable to shareholdersQ3 2019 + Net income (loss) attributable to shareholdersQ2 2019) ÷ (Net revenuesQ1 2020 + Net revenuesQ4 2019 + Net revenuesQ3 2019 + Net revenuesQ2 2019)
= 100 × ( + + + ) ÷ ( + + + ) =

2 Click competitor name to see calculations.


Net Income (Loss) Attributable to Shareholders
The net income figures exhibit significant volatility over the reported quarters. Early in the period, a major positive spike occurs in September 2016, reaching over 15 billion USD, which is an outlier compared to other quarters that mostly show losses or modest income. Apart from this peak, the net income demonstrates a general trend of negative or low positive results, frequently dipping into substantial losses, particularly noticeable in the first quarters of 2017, 2018, and 2019. The last quarter shows some recovery with a positive net income of 378 million USD in March 2020, yet this value remains modest relative to the large fluctuations observed earlier.
Net Revenues
Net revenues display a relatively stable pattern with moderate growth tendencies. Beginning around 3.4 billion USD in early 2016, revenues increase gradually, reaching peaks above 4.3 billion USD in some quarters such as December 2017 and December 2019. Although revenues fluctuate on a quarter-to-quarter basis, the variation is moderate, and no drastic decreases are evident. This steadiness contrasts with the volatility in net income, indicating consistent top-line performance.
Net Profit Margin
The net profit margin percentage mirrors the volatility seen in net income. High positive margins are found in 2016, particularly around September and December, where margins exceed 100%, coinciding with the large net income spike. However, subsequent periods show marked declines, with persistent negative margins from early 2017 through most of 2019. Negative profit margins reach magnitudes over 50% in some quarters, signaling substantial losses relative to revenues. In the final period reported, the margin improves somewhat, though it remains negative at approximately -15%, indicating ongoing challenges in profitability despite steady revenue streams.
Overall Analysis
The data reveals a disconnect between revenue generation and profitability. While revenues remain relatively stable and even show growth trends, net income and profit margins are highly erratic, with extended periods of losses and only sporadic profitable quarters. This suggests that factors beyond sales volume, such as costs, expenses, or one-time events, significantly impact the company’s profitability. The exceptional net income in late 2016 appears to be an anomaly rather than a sustainable trend. The persistent negative margins in subsequent periods highlight financial pressures that may warrant deeper operational review.

Return on Equity (ROE)

Allergan PLC, ROE calculation (quarterly data)

Microsoft Excel
Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016
Selected Financial Data (US$ in thousands)
Net income (loss) attributable to shareholders
Shareholders’ equity
Profitability Ratio
ROE1
Benchmarks
ROE, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31), 10-K (reporting date: 2016-12-31), 10-Q (reporting date: 2016-09-30), 10-Q (reporting date: 2016-06-30), 10-Q (reporting date: 2016-03-31).

1 Q1 2020 Calculation
ROE = 100 × (Net income (loss) attributable to shareholdersQ1 2020 + Net income (loss) attributable to shareholdersQ4 2019 + Net income (loss) attributable to shareholdersQ3 2019 + Net income (loss) attributable to shareholdersQ2 2019) ÷ Shareholders’ equity
= 100 × ( + + + ) ÷ =

2 Click competitor name to see calculations.


The financial data indicates notable volatility in net income attributable to shareholders over the observed quarters. Initially, the net income showed significant positive values, peaking strongly at one quarter with over 15 billion USD. However, this was followed by sharp declines and several quarters of negative net income, highlighting fluctuations and potential operational or market challenges.

Shareholders' equity demonstrated a generally downward trend throughout the period. Starting from approximately 77.45 billion USD, equity values gradually decreased to close to 58 billion USD by the final quarter. This decline suggests potential erosion of the company's net asset base, which may be attributed to accumulated losses or other factors affecting retained earnings.

Return on equity (ROE) showed considerable variability. Early quarters reflect positive ROE values peaking near 20%, indicating periods of strong profitability relative to shareholders' equity. Later periods reveal a shift to predominantly negative ROE, with the lowest around -15.82%, signalling financial strain and challenges in generating returns for shareholders. The negative ROE coincides with quarters of negative net income, confirming the impact of losses on profitability ratios.

Net Income Trends
An initial spike in net income was followed by persistent volatility and predominantly negative returns in later periods, indicating inconsistent earnings performance.
Shareholders’ Equity Trends
A gradual decline over time points to a reduction in net assets, potential losses retained in equity, or other equity-depleting events.
Return on Equity (ROE) Pattern
ROE shifted from strong positive values in the first half of the period to sustained negative values in the latter half, reflecting diminished profitability and efficiency in generating shareholder returns.

Overall, the data illustrates a transition from profitability to financial challenges, with declining equity and ROE metrics underscoring periods of loss and reduced returns to shareholders. The trends suggest a need for focused attention on profitability restoration and equity preservation moving forward.


Return on Assets (ROA)

Allergan PLC, ROA calculation (quarterly data)

Microsoft Excel
Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016
Selected Financial Data (US$ in thousands)
Net income (loss) attributable to shareholders
Total assets
Profitability Ratio
ROA1
Benchmarks
ROA, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31), 10-K (reporting date: 2016-12-31), 10-Q (reporting date: 2016-09-30), 10-Q (reporting date: 2016-06-30), 10-Q (reporting date: 2016-03-31).

1 Q1 2020 Calculation
ROA = 100 × (Net income (loss) attributable to shareholdersQ1 2020 + Net income (loss) attributable to shareholdersQ4 2019 + Net income (loss) attributable to shareholdersQ3 2019 + Net income (loss) attributable to shareholdersQ2 2019) ÷ Total assets
= 100 × ( + + + ) ÷ =

2 Click competitor name to see calculations.


Net Income (Loss) Attributable to Shareholders
The net income demonstrates significant volatility over the observed quarters. Starting with a positive figure of approximately 256 million USD in early 2016, the net income sharply declines into a substantial loss of over 500 million USD in the subsequent quarter. This is followed by an extraordinary positive spike, reaching around 15.2 billion USD in late 2016, after which the income fluctuates mainly in negative territory for the majority of the following quarters. Losses peak in several quarters such as late 2017 and throughout 2019, before showing a modest recovery with a positive net income of 378 million USD in early 2020. This pattern indicates episodic gains and persistent challenges impacting profitability.
Total Assets
Total assets exhibit a gradual but consistent decline from approximately 136 billion USD at the beginning of 2016 down to around 88.4 billion USD by the first quarter of 2020. This represents a significant contraction in the asset base over the five-year period. The steady decrease may be indicative of asset sales, depreciation, impairments, or other balance sheet adjustments, reflecting a strategic downsizing or restructuring effort.
Return on Assets (ROA)
Return on assets illustrates a pronounced deterioration in asset profitability throughout the analyzed period. Initially, ROA values are positive, peaking above 11% in the last quarter of 2016. However, from early 2017 onwards, the ratio declines sharply, entering negative territory and remaining predominantly below zero through 2019. By 2020, there is a minor improvement but ROA still stays negative at around -2.8%. The declining and predominantly negative ROA mirrors the trend in net income and suggests reduced efficiency in utilizing assets to generate profit.
Overall Trends and Insights
The company experienced considerable financial instability with large fluctuations in profitability. Despite a notable high in late 2016, recurring net losses dominated subsequent quarters, adversely affecting overall performance metrics. The consistent decline in total assets combined with deteriorating ROA underlines challenges in maintaining asset productivity and generating earnings. The slight improvement observed in early 2020 may be an early indication of recovery but remains modest relative to prior periods. These trends suggest the need for careful evaluation of operational strategy, asset management, and cost control measures to restore sustainable financial health.